Recent Updates on Corticosteroid-Induced Neuropsychiatric Disorders and Theranostic Advancements through Gene Editing Tools

Abstract

The vast use of corticosteroids (CCSs) globally has led to an increase in CCS-induced neuropsychiatric disorders (NPDs), a very common manifestation in patients after CCS consumption. These neuropsychiatric disorders range from depression, insomnia, and bipolar disorders to panic attacks, overt psychosis, and many other cognitive changes in such subjects. Though their therapeutic importance in treating and improving many clinical symptoms overrides the complications that arise after their consumption, still, there has been an alarming rise in NPD cases in recent years, and they are seen as the greatest public health challenge globally; therefore, these potential side effects cannot be ignored. It has also been observed that many of the neuronal functional activities are regulated and controlled by genomic variants with epigenetic factors (DNA methylation, non-coding RNA, and histone modeling, etc.), and any alterations in these regulatory mechanisms affect normal cerebral development and functioning. This study explores a general overview of emerging concerns of CCS-induced NPDs, the effective molecular biology approaches that can revitalize NPD therapy in an extremely specialized, reliable, and effective manner, and the possible gene-editing-based therapeutic strategies to either prevent or cure NPDs in the future.

Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models

“…High doses or chronic corticosteroid use is associated with significant adverse effects that can limit their long-term use including excessive weight gain, adrenal insufficiency, behavioral changes, Cushing’s syndrome, stunted growth, and osteoporosis [ 16–18 ]. Psychiatric disorders induced by chronic steroid use range in severity and can include depression, insomnia, mania, panic attacks, and even psychosis [ 19 , 20 ]. Exacerbation of DMD-associated behavioral problems with corticosteroids complicate corticosteroid use.…”

A Behavioral Test Score Could Be Linked to the Protein Expression Value of p62 and GLAST in the Brain of Mice with Neuropsychiatric Disorders-Related Behaviors

“…Neuropsychiatric disorders are globally public-health concern [1]. Schizophrenia is one of the well-known neuropsychiatric disorders with the most severe disabilities that may affect approximately 1% of the human population, which is also complicated by comorbid drug use problems [2].…”